BiotechnologyAptamer developed by HKBU for treating rare bone disease ‘X-linked hypophosphatemia’ receives Orphan Drug Designation and Rare Pediatric Disease Designation by U.S. FDA
A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People’s Hospital Affiliated to School of Medicine at Shanghai Jiao Tong University (Shanghai Sixth People’s Hospital) has discovered that an aptamer developed by HKBU can be used to treat X-linked hypophosphatemia (XLH), a rare bone disease. The aptamer, originally developed to treat osteogenesis imperfecta, has been granted Orphan Drug Designation and Pediatric Rare Disease Designation by the U.S. Food and Drug Administration (FDA). Professor Zhang Ge, Associate...